Variant Synonymizer: Platform to identify mutations defined in different ways is available now!
Over 2,000 gene–disease validation summaries are now available—no login required!
Familial hemophagocytic lymphohistiocytosis type 3 (FHL3) is an autosomal recessive hyperinflammatory disorder caused by biallelic pathogenic variants in UNC13D, encoding Munc13-4. Patients present in infancy or childhood with fever, splenomegaly, cytopenias, hyperferritinemia, hypofibrinogenemia, and variable central nervous system involvement. Deep intronic and structural variants may underlie otherwise unexplained cases, highlighting the need for comprehensive genetic testing.
Inheritance mode: Autosomal recessive
UNC13D deficiency has been confirmed in >80 probands from >60 unrelated families worldwide, including homozygous and compound heterozygous LoF variants that segregate with disease in multiple affected sibships (PMID:15466010, PMID:15632205, PMID:17993578). Founder splice-site mutations c.754-1G>C and deep intronic c.118-308C>T account for a large fraction of Korean FHL3 cases (PMID:23180437).
Segregation analyses across consanguineous and non-consanguineous families demonstrate co-segregation of UNC13D mutations with disease. A recurrent canonical splice-site variant, c.753+1G>T, abolishes correct mRNA splicing and leads to absent Munc13-4 protein in patient cells (PMID:15466010). The allelic spectrum includes nonsense, frameshift, splice-site, missense, inversion, and deep intronic mutations, cumulatively accounting for ~25% of PRF1/STX11-negative FHL families (PMID:17993578). Recurrent founder alleles support a robust genotype-phenotype correlation.
Munc13-4 physically interacts with Rab27a to prime secretory granules for Ca²⁺-dependent exocytosis in NK and CD8⁺ T cells. Loss of Munc13-4 impairs CTL and NK cell degranulation, as shown by cytotoxicity assays and β-hexosaminidase release in RBL-2H3 cells (PMID:14622591, PMID:14699162). Deep intronic and inversion mutations abolish lymphocyte-specific UNC13D transcription and Munc13-4 expression, confirming pathogenicity of non-coding variants (PMID:21931115).
Early molecular diagnosis of UNC13D mutations expedites initiation of HLH-2004–based chemoimmunotherapy and timely allogeneic hematopoietic stem cell transplantation, which dramatically improves survival. UNC13D testing is recommended in patients with atypical CNS presentation mimicking ADEM (PMID:19023578) and in adult-onset HLH cases with hypomorphic mutations (PMID:21881043).
The gene–disease association between UNC13D and FHL3 is Definitive based on extensive genetic and functional concordance accumulated over >15 years. Key Take-Home: UNC13D mutation screening should be performed promptly in pediatric and adult patients with suspected HLH to guide curative HSCT.
Gene–Disease AssociationDefinitiveBiallelic UNC13D variants reported in >80 probands from >60 unrelated families with segregation and functional concordance Genetic EvidenceStrongHomozygous and compound heterozygous LoF UNC13D variants segregate in multiple families, including recurrent founder mutations c.754-1G>C and c.118-308C>T (PMID:15466010, PMID:15632205, PMID:17993578) Functional EvidenceStrongIn vitro CTL/NK degranulation assays and Rab27a binding studies confirm loss of Munc13-4 function due to UNC13D mutations (PMID:15466010, PMID:14622591) |